Nanobiotix S.A.

    Jurisdiction
    France
    LEI
    969500667RSYIH8YL895
    ISIN
    FR0011341205 (NANO.PA)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_down 46 / 100
    Worse than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €24.60M
    Gross margin
    108.6%
    EBIT
    -€98.47M
    EBIT margin
    -400.3%
    Net income
    -€107.83M
    Net margin
    -438.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €28.10M +14.2% -€28.39M -73.7%
    €93.42M +232.5% €25.49M -189.8%
    €86.71M -7.2% €14.90M -41.5%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: April 3, 2025

    Add to watchlist

    Notifications